PolyPid (PYPD) Accumulated Expenses (2019 - 2026)
PolyPid (PYPD) posted Accumulated Expenses of $3.6 million for Q1 2026, up 29.96% sequentially from $2.7 million in Q4 2025, and up 19.75% YoY from $3.0 million in Q1 2025.
PolyPid (PYPD) Accumulated Expenses (2019 - 2026) Analysis & Trends
PolyPid has reported Accumulated Expenses for 8 years, with the latest figure at $3.6 million in Q1 2026.
- Quarterly Accumulated Expenses rose 19.75% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (up 19.75% YoY) and the FY2025 annual result came in at $2.7 million, up 6.55% from the prior year.
- Accumulated Expenses improved to $3.6 million in Q1 2026 per PYPD's latest filing, from $2.7 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $4.1 million in Q2 2022 and troughed at $1.4 million in Q1 2023.
- A 5-year average of $2.7 million and a median of $2.7 million in 2022 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses sank 56.74% in 2023, then jumped 86.89% in 2024.
- Over 5 years, Accumulated Expenses stood at $2.4 million in 2022, then decreased by 18.86% to $2.0 million in 2023, then surged by 30.19% to $2.6 million in 2024, then increased by 6.55% to $2.7 million in 2025, then advanced by 29.96% to $3.6 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $3.6 million, $2.7 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PolyPid | 113.86 Mn | 107.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.65 Mn |
| Mar 31, 2026 | 3.55 Mn |
| Dec 31, 2025 | 2.73 Mn |
| Sep 30, 2025 | 2.21 Mn |
| Jun 30, 2025 | 2.97 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | 2.57 Mn |
| Sep 30, 2024 | 2.77 Mn |
| Jun 30, 2024 | 2.98 Mn |
| Mar 31, 2024 | 2.61 Mn |
| Dec 31, 2023 | 1.97 Mn |
| Sep 30, 2023 | 2.02 Mn |
| Jun 30, 2023 | 1.84 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | 2.43 Mn |
| Sep 30, 2022 | 2.72 Mn |
| Jun 30, 2022 | 4.11 Mn |
| Mar 31, 2022 | 3.23 Mn |
| Dec 31, 2021 | 3.94 Mn |
| Sep 30, 2021 | 3.49 Mn |